Prevalência de sarcoma de Kaposi em pacientes com aids e fatores associados, São Paulo-SP, 2003-2010*

Tancredi, Mariza Vono; Pinto, Valdir Monteiro; Silva, Mariliza Henrique da; Pimentel, Sidnei Rana; Silva, Tatiana Santana Bueno da; Ito, Sandra Mitie Akamatsu; Golub, Jonathan E.; Toscano, Ana Luiza de Castro Conde

doi:10.5123/s1679-49742017000200015

Cited by 16 publications

(10 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The figures obtained in this study are much lower than that from Sao Paulo, Brazil, where the prevalence of KS among persons on HAART was reported to be 6%. 5 In North America, the cumulative incidence of KS was recorded to be 4.4 % in 2015. 19 In LMICs, access to HAART is suboptimal and sero-prevalence of HHV-8 is reported to be as high as 20-30%.…”

Section: Discussionmentioning

confidence: 99%

“…3 The prevalence of KS is higher among the human immunodeficiency virus (HIV) infected population than the general population and it varies widely among different HIV infected populations. [4][5][6][7][8][9] It is not certain what factors predict the development of KS among the HIV infected persons. In the late stages of the HIV infection, KS runs a very aggressive course, suggesting the modifying role of lowered immunity in its development and progression.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Prevalence and predictors of Kaposi’s sarcoma among HIV patients receiving care at a tertiary hospital in Jos, Nigeria

Daboer

Chingle

Puepet

et al. 2021

Journal of Global Health Reports

View full text Add to dashboard Cite

BackgroundKaposi's sarcoma became prevalent with the appearance of human immune deficiency virus (HIV) in the 1980s. However, the widespread use of the highly active antiretroviral therapy (HAART) reduced its prevalence in communities with good access to the antiretroviral drugs. The objective of this study was to determine the prevalence and predictors of Kaposi's sarcoma among persons receiving HIV care at a tertiary hospital in Jos, Nigeria. MethodsThe study used a cross-sectional study design, based on secondary data related to patients who had received HIV care between January 2004 and December 2017. Logistic regression was then used to determine the variables that were predictors of Kaposi's sarcoma risk. ResultsThe prevalence of Kaposi's sarcoma among the patients was 1.2% (95% confidence interval, CI=1.06-1.34). Patients whose baseline viral loads were higher than 10,000 copies/mm 3 were three times more likely to develop Kaposi's sarcoma than those with lesser viral load (OR: 3.13, CI: 2.19-4.47). Gender, duration of HAART and education had modifying effect on the Kaposi's sarcoma risk. ConclusionsKaposi's sarcoma is a substantial public health problem among the HIV population in Jos. Universal access to HAART by the Federal Government of Nigeria and its partners is recommended to reduce its prevalence. In addition, education, skill acquisition and income generating programs should be targeted at girls and women by governments and other stakeholders in order to reduce the inequality that worsens their vulnerability to HIV infection and Kaposi's sarcoma.Kaposi's sarcoma (KS) is an angio-proliferative malignancy that affects the endothelium of blood vessels. It predominantly affects the skin at different sites and can progress and regress depending on the immunity of the host. 1 KS is one of the most common malignancies in the world and the most important AIDS defining cancer (ADC). 2 The Human Herpes Virus type 8 (HHV-8) is a necessary, but not sufficient cause of KS. 3 The prevalence of KS is higher among the human immunodeficiency virus (HIV) infected population than the general population and it varies widely among different HIV infected populations. [4][5][6][7][8][9] It is not certain what factors predict the development of KS among the HIV infected persons. In the late stages of the HIV infection, KS runs a very aggressive course, suggesting the modifying role of lowered immunity in its development and progression. 9 However, some HIV patients treated with the highly active antiretroviral therapy (HAART), and who experience a substantial restoration of the CD4+ cell count have also been reported to develop KS, even at this stage, suggesting that there may be other factors at play. 2 The advent of HAART has reduced the incidence of KS in Europe and North America, but disaggregated data even in such societies have provided evidence of stagnant or even worsening incidence of KS among certain population subgroups. 9 This is often attributed to the inequality in access to HAART in those populations. In l...

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Prevalence and predictors of Kaposi’s sarcoma among HIV patients receiving care at a tertiary hospital in Jos, Nigeria

Daboer

Chingle

Puepet

et al. 2021

Journal of Global Health Reports

View full text Add to dashboard Cite

show abstract

“…O sarcoma de Kaposi (SK) é um tumor mesenquimal causado pelo herpes-vírus humano tipo 8 1 , que se manifesta como lesão vascular multifocal frequente em sítios mucocutâneos, mas que também pode afetar linfonodos e vísceras 2 . Foi descrito pela primeira vez em 1872, permanecendo como um tumor raro até o surgimento do vírus da imunodeficiência humana (do inglês, human immunodeficiency virus -HIV) no início dos anos 1980 2 .…”

Section: Introductionunclassified

“…O SK pode manifestar-se de quatro formas distintas: clássico, endêmico, iatrogênico e epidêmico 3 . Considerada a forma mais agressiva da doença, o SK epidêmico está associado ao HIV e é mais frequente entre homens que fazem sexo com homens 1 .…”

Section: Introductionunclassified

“…Para o ano 2018, estimaram-se 778 casos novos de SK e 137 mortes por esta causa no Brasil 4 . Um estudo realizado com 3.557 casos de síndrome da imunodeficiência adquirida (aids) em centro de referência da cidade de São Paulo, Brasil, estimou prevalência de SK igual a 6,0% 1 As variáveis investigadas no momento do diagnóstico do SK foram: sexo (masculino ou feminino), idade (contínua e categorizada conforme a mediana em <50 anos e ≥50 anos), raça/cor da pele (categorizada em branca e preta e/ou parda), escolaridade (categorizada em nenhuma, ensino fundamental incompleto e/ou completo e ensino médio e/ou superior), situação conjugal (categorizada em vive com companheiro(a) e vive sem companheiro(a)), sorologia anti-HIV (positiva ou negativa), contagem de células CD4 (categorizada em <200 células/mm 3 e ≥200 células/mm 3 ), carga viral do HIV indetectável (sim ou não) e uso de terapia antirretroviral altamente ativa (sim ou não). Inicialmente, foi realizada uma análise exploratória dos dados por meio da descrição da distribuição das variáveis na população de estudo.…”

Section: Introductionunclassified

See 1 more Smart Citation

Sobrevida e Fatores Prognósticos de Pacientes com Sarcoma de Kaposi Atendidos em um Centro de Assistência de Alta Complexidade em Oncologia

Noronha¹,

Borges²,

Ferreira³

et al. 2020

Rev. Brasileira.De.Cancerologia

View full text Add to dashboard Cite

Introdução: A sobrevida do sarcoma de Kaposi ainda não e bem conhecida porque os poucos estudos que avaliaram-na foram, em maioria, conduzidos com pessoas vivendo com vírus da imunodeficiência humana (HIV). Objetivo: Avaliar a sobrevida e os fatores prognósticos pré-tratamento de pacientes com sarcoma de Kaposi associado ou não ao HIV. Método: Estudo retrospectivo realizado em uma coorte hospitalar de 81 pacientes diagnosticados com sarcoma de Kaposi entre 2000 e 2014, atendidos em um centro de assistência de alta complexidade em oncologia da cidade do Rio de Janeiro, Brasil. A probabilidade de sobrevida em cinco anos foi estimada por meio do método de Kaplan-Meier. O modelo semiparamétrico de riscos proporcionais de Cox estimou hazard ratios (HR) e respectivos intervalos de 95% de confiança (IC95%). Resultados: A sobrevida global em cinco anos foi de 50,9% (IC95%: 38,2-62,3). Os fatores associados ao óbito foram idade ≥50 anos (HR: 4,19; IC95%: 1,5-11,29) e sorologia anti-HIV positiva (HR: 5,82; IC95%: 1,90-17,85). Conclusão: A coorte apresentou sobrevida baixa. O prognostico foi influenciado pela idade ≥50 anos e sorologia anti-HIV positiva, devendo esses fatores serem considerados na avaliação de risco pré-tratamento.

show abstract

Rapidly progressive Kaposi’s sarcoma associated with human immunodeficiency syndrome

Pinheiro¹,

Paiva²,

Ferreira³

et al. 2023

Anais Brasileiros de Dermatologia

View full text Add to dashboard Cite

Prevalência de sarcoma de Kaposi em pacientes com aids e fatores associados, São Paulo-SP, 2003-2010*

Abstract: KS has a high prevalence in São Paulo-SP; strategies for early HIV diagnosis may reduce this prevalence.

Cited by 16 publications

References 3 publications

Prevalence and predictors of Kaposi’s sarcoma among HIV patients receiving care at a tertiary hospital in Jos, Nigeria

Prevalence and predictors of Kaposi’s sarcoma among HIV patients receiving care at a tertiary hospital in Jos, Nigeria

Sobrevida e Fatores Prognósticos de Pacientes com Sarcoma de Kaposi Atendidos em um Centro de Assistência de Alta Complexidade em Oncologia

Rapidly progressive Kaposi’s sarcoma associated with human immunodeficiency syndrome

Contact Info

Product

Resources

About